AxoGen (NASDAQ:AXGN) and Semler Scientific (OTCMKTS:SMLR) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, dividends, earnings and profitability.
Risk & Volatility
AxoGen has a beta of 0.36, meaning that its share price is 64% less volatile than the S&P 500. Comparatively, Semler Scientific has a beta of 0.46, meaning that its share price is 54% less volatile than the S&P 500.
This table compares AxoGen and Semler Scientific’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation & Earnings
This table compares AxoGen and Semler Scientific’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|AxoGen||$83.94 million||9.01||-$22.40 million||($0.54)||-35.96|
|Semler Scientific||$21.49 million||12.92||$5.01 million||$0.66||65.15|
Semler Scientific has lower revenue, but higher earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than Semler Scientific, indicating that it is currently the more affordable of the two stocks.
This is a breakdown of recent ratings for AxoGen and Semler Scientific, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
AxoGen currently has a consensus price target of $38.00, suggesting a potential upside of 95.67%. Semler Scientific has a consensus price target of $44.00, suggesting a potential upside of 2.33%. Given AxoGen’s higher possible upside, analysts plainly believe AxoGen is more favorable than Semler Scientific.
Institutional and Insider Ownership
87.2% of AxoGen shares are held by institutional investors. Comparatively, 12.0% of Semler Scientific shares are held by institutional investors. 7.9% of AxoGen shares are held by insiders. Comparatively, 13.9% of Semler Scientific shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Semler Scientific beats AxoGen on 9 of the 13 factors compared between the two stocks.
AxoGen Company Profile
AxoGen, Inc. develops and markets surgical solutions for peripheral nerve injuries. The company's surgical solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its solutions also comprise Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues and modulate inflammation in the surgical bed. In addition, the company offers AcroVal neurosensory and motor testing system, which consists of AcroGrip for use in hand grip strength measurement; AcroPinch for measuring pinch strength; and Pressure-Specified Sensory Device, a somatosensory evaluation and measurement device. Further, it provides AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals in the United States, Canada, the United Kingdom and other European countries, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.
Semler Scientific Company Profile
Semler Scientific, Inc. develops, manufactures, and markets proprietary products that assist healthcare providers to evaluate and treat patients with chronic diseases in the United States. Its products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition. The company's products serve cardiologists, internists, nephrologists, endocrinologists, podiatrists, and family practitioners, as well as healthcare insurance plans, integrated delivery networks, independent physician groups, and companies contracting with the healthcare industry, such as risk assessment groups. It offers its products through salespersons and distributors. Semler Scientific, Inc. was founded in 2007 and is headquartered in San Jose, California.
Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.